Learn more about whether Alvotech or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

PE-backed specialty pharma company Kelso Pharma appointed Giovanni Mauri as general manager of its recently acquired Italian ...

Regeneron is to ask the FDA for clearance ... Myron Cohen,who leads the monoclonal antibody efforts for the NIH-sponsored COVID Prevention Network (CoVPN) and is director of the Institute ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...